Risk factors

Estrella Immunopharma (ESLA) risk factors

Item 1A of every Estrella Immunopharma, Inc. 10-K on file, and what changed from one year to the next.

Open ESLA in Gloomberb →
  • FY2025 10-K risk factors

    75 risks, 5 new, 10 dropped, 18 reworded since the prior year. Estrella added risks regarding AI security, inflation, Nasdaq listing compliance, and clinical/licensing dependencies. The company dropped several risks related to its equity line purchase agreement with White Lion and warrant exercises.

    Filed Mar 18, 2026
  • FY2024 10-K risk factors

    80 risks. Estrella Immunopharma relies heavily on its Common Stock Purchase Agreement with White Lion, its ARTEMIS platform, and its partnership with Eureka for research and development.

    Filed Sep 27, 2024